Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer

计划入组 428 人 · 首次发布于 2024 年 3 月 22 日

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ

计划入组 21 人 · 首次发布于 2023 年 7 月 12 日

HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer

计划入组 59 人 · 首次发布于 2020 年 5 月 27 日

EuPort

PORT-8

ADE-HYPT

PHARMED IMPORT & EXPORT PTE LTD

Singapore

AUSTRALASIAN IMPORT EXPORT PTY LTD

Australia

TLCH IMPORT AND EXPORT PTY LTD

Australia

Hypofractionated Radiotherapy Reduces Treatment Time and Toxicity While Maintaining Survival in Limited-Stage Small Cell Lung Cancer

Shorter Course of Radiation Therapy Proves Safe and Effective for Post-Surgery Prostate Cancer Patients

Hypofractionated Radiotherapy Shows Promise in Post-Prostatectomy and Localized Prostate Cancer Treatment